Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 4/20 | 0.34 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2273461 | 1.00 | GABRR1 (0.34) | GABRR1GABRR2LMNAPLGPLAT | |
| SCHEMBL6476 | 1.00 | GABRR1 (0.34) | GABRR1GABRR2LMNAPLGPLAT | |
| SCHEMBL3102587 | 1.00 | GABRR1 (0.34) | GABRR1GABRR2LMNAPLGPLAT | |
| SCHEMBL14678324 | 0.90 | HSD17B10 (0.39) | LMNARIPK1DPP4CYP2C19HSD17B10 | |
| SCHEMBL2386007 | 0.90 | HSD17B10 (0.39) | LMNARIPK1DPP4CYP2C19HSD17B10 | |
| SCHEMBL6102565 | 0.88 | GABRR1 (0.32) | GABRR1GABRR2LMNAPLGPLAT | |
| SCHEMBL505509 | 0.88 | GABRR1 (0.32) | GABRR1GABRR2LMNAPLGPLAT | |
| SCHEMBL8197140 | 0.88 | GABRR1 (0.32) | GABRR1GABRR2LMNAPLGPLAT | |
| SCHEMBL860060 | 0.86 | RIPK1 (0.33) | LMNARIPK1CYP2C19HSD17B10 | |
| SCHEMBL344649 | 0.86 | RIPK1 (0.33) | LMNARIPK1CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2013-07-04 | — | — | US | disclosed |
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-11-22 | — | — | US | disclosed |
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | GLAXO GROUP LIMITED (GB) | 2010-10-07 | — | — | US | disclosed |
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | GABRR1 4405/4885GABRR2 4572/4885LMNA 2029/4885 |
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, COASY | GABRR1 717/4885GABRR2 802/4885LMNA 3267/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | GABRR1 2136/4885GABRR2 2007/4885LMNA 4652/4885 |
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | TOP1, TOP2A, NDC1 | GABRR1 3851/4885GABRR2 4179/4885LMNA 1679/4885 |
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | GABRR1 1940/4885GABRR2 2101/4885LMNA 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.